Wei Zhang | Health Professions | Best Researcher Award

Posted on by ScienceFather

Prof. Dr. Wei Zhang | Health Professions | Best Researcher Award

Professor at School of Nursing, Jilin University, China

Dr. Zhang Wei is a distinguished professor at Jilin University’s School of Nursing, where she leads the Department of Obstetrics and Gynecology Nursing. Her extensive career encompasses significant contributions to maternal and child health nursing, mental health nursing, and nursing education. Dr. Zhang has published over 40 papers as the first or corresponding author, with more than 30 in SCI-indexed journals, underscoring her commitment to advancing nursing science.

Professional Profile

Education

Dr. Zhang’s academic journey began with a bachelor’s degree in Maternal and Child Health from Jilin University’s Norman Bethune College of Medicine in 2002. She then earned a master’s degree in Women’s Health from the same institution in 2005. Pursuing further specialization, she obtained her Ph.D. in Immunology from Jilin University’s First Hospital in 2012. Demonstrating a commitment to interdisciplinary research, Dr. Zhang completed a postdoctoral fellowship in Social Medicine and Health Management at Jilin University’s School of Public Health between 2015 and 2021.

Professional Experience

Dr. Zhang’s professional trajectory at Jilin University is marked by progressive academic appointments. She began as a teaching assistant in the School of Nursing in 2005, advanced to lecturer in 2008, and was promoted to associate professor in 2014. In September 2023, she achieved the rank of professor. Throughout her tenure, Dr. Zhang has been instrumental in curriculum development and has served on both the Academic and Teaching Committees of the School of Nursing.

Research Interests

Dr. Zhang’s research interests are diverse and impactful. She focuses on maternal and child health nursing, emphasizing health promotion and care for women during critical life stages such as pregnancy, perimenopause, and adolescence. Her work in mental health nursing addresses psychological well-being, while her studies in chronic disease management concentrate on nursing care and preventive measures for female reproductive system cancers, including breast and gynecological tumors. Additionally, Dr. Zhang is dedicated to nursing education, exploring innovative teaching models and methods, particularly in blended learning environments.

Research Skills

Dr. Zhang possesses a robust set of research skills, including proficiency in systematic reviews and meta-analyses, as evidenced by her publications on topics like the effectiveness of family-centered interventions for caregivers and internet-based cognitive behavioral therapy for cancer patients. She is adept at both qualitative and quantitative research methodologies, enabling her to conduct comprehensive studies that inform evidence-based nursing practices.

Awards and Honors

Throughout her career, Dr. Zhang has received numerous accolades recognizing her contributions to nursing education and research. Notably, she was awarded the third prize in the 17th Jilin Province Higher Education Scientific Research Achievement Awards in November 2022 for her work on blended teaching models in obstetrics and gynecology nursing. She also received the Excellence Award for Undergraduate “Classroom Teaching Quality” at Jilin University for the 2021-2022 academic year, reflecting her dedication to teaching excellence.

Conclusion

Dr. Zhang Wei’s exemplary career in nursing is characterized by her unwavering commitment to advancing healthcare through research, education, and leadership. Her multidisciplinary expertise and dedication to improving women’s health have significantly impacted both the academic community and clinical practice. Dr. Zhang continues to inspire future generations of nurses and healthcare professionals through her innovative work and steadfast dedication to the field.

Publication Top Notes

  1. “Effectiveness of Meaning-Centered Interventions on Existential Distress and Mental Health Outcomes in Cancer Survivors and Their Family Caregivers: A Systematic Review and Meta-Analysis of Randomized Controlled Trials”
    • Authors: Ziqi Wang, Dongsheng Xu, Shuanghan Yu, Yantong Liu, Yujie Han, Wei Zhao, Wei Zhang
    • Year: 2025
    • Journal: Worldviews on Evidence-Based Nursing
  2. “Effects of Nurse-Led e-Health Interventions on the Health-Related Outcomes of Pregnant Women: A Systematic Review”
    • Authors: Yujie Han, Qi Tian, Mengmeng Xu, Ziqi Wang, Wei Zhang
    • Year: 2025
    • Journal: Journal of Clinical Nursing
  3. “The Impact of Simulation-Based Learning on Nursing Decision-Making Ability: A Meta-Analysis”
    • Authors: Wei Zhao, Mengmeng Xu, Qi Tian, Ziqi Wang, Wei Zhang
    • Year: 2024
    • Journal: Clinical Simulation in Nursing
  4. “Effectiveness of Family-Centered Interventions for Family Caregivers: A Systematic Review and Meta-Analysis of Randomized Controlled Trials”
    • Authors: Ziqi Wang, Shuanghan Yu, Yantong Liu, Yujie Han, Wei Zhao, Wei Zhang
    • Year: 2024
    • Journal: Journal of Clinical Nursing
    • Citations: 2

 

Varun Prabhuji | Conservative Dentistry | Best Researcher Award

Posted on by ScienceFather

Dr. Varun Prabhuji | Conservative Dentistry | Best Researcher Award

Director at Roots to Cusps Private Limited, India

Dr. Varun Prabhuji is an accomplished dental researcher and clinician with a distinguished academic background and a strong focus on advancing dental science through innovative technology. With multiple patents, trademarks, and research publications, he has made significant contributions to the field of endodontics and minimally invasive dentistry. Dr. Prabhuji’s work emphasizes the development of cutting-edge dental devices and methodologies aimed at improving patient outcomes and clinical efficiency. He is the Director of Roots to Cusps® Private Limited, where he leads efforts in dental innovation, and a Trustee of the Prabhuji Foundation, through which he supports community dental care initiatives. His research has earned him prestigious awards and substantial funding, reflecting his commitment to both academic excellence and practical advancements in dental care. Dr. Prabhuji continues to push the boundaries of dental research while fostering a vision for accessible and high-quality dental solutions.

Professional Profile

Education

Dr. Varun Prabhuji earned his Bachelor of Dental Surgery (BDS) degree from Rajiv Gandhi University of Health Sciences (RGUHS), where he consistently ranked at the top across multiple subjects. During his undergraduate studies, he received several notable accolades, including the IDA Colgate Scholarship and the ISP Merit Award. Currently, he is pursuing a Master of Dental Surgery (MDS) with a focus on advanced endodontic procedures and dental material innovations. His academic journey is marked by a commitment to excellence, with a focus on integrating advanced technology with clinical practice. Throughout his educational career, Dr. Prabhuji has demonstrated an exceptional aptitude for research, leading to the development of patented technologies and innovations. His strong academic foundation, combined with a dedication to continuous learning, positions him as a leader in the dental research community.

Professional Experience

Dr. Varun Prabhuji has amassed substantial experience in both clinical practice and research. As the Director of Roots to Cusps® Private Limited, he spearheads the development of innovative dental products, including patented technologies like PriciGuide® and PriciCrown®. His professional journey includes hands-on clinical work in advanced endodontics and the application of cutting-edge dental materials. In addition to his entrepreneurial role, Dr. Prabhuji actively contributes to the academic community through research publications and conference presentations. He also serves as a Trustee at the Prabhuji Foundation, where he oversees initiatives that provide free dental care to underserved communities. His leadership extends to organizing national and international conferences, fostering dialogue on the latest advancements in dentistry. With a unique blend of clinical expertise and innovative thinking, Dr. Prabhuji continues to drive impactful changes in dental research and patient care.

Research Interests

Dr. Varun Prabhuji’s research interests lie at the intersection of advanced endodontics, dental biomaterials, and minimally invasive dentistry. His work is particularly focused on developing innovative dental devices and techniques that enhance precision and patient outcomes. Dr. Prabhuji is passionate about guided endodontic procedures, a field where he has contributed patented solutions like PriciGuide®. His research extends to exploring novel dental materials and their applications in restorative dentistry, with an emphasis on improving durability and biocompatibility. Another area of interest involves integrating digital technologies into clinical workflows to streamline procedures and enhance diagnostic accuracy. Through his research, Dr. Prabhuji aims to bridge the gap between scientific discovery and practical implementation, ensuring that advancements in dental science translate into tangible benefits for both clinicians and patients. His commitment to innovation is reflected in his ongoing pursuit of new methodologies to improve oral health care.

Research Skills

Dr. Varun Prabhuji possesses a diverse skill set in dental research, encompassing both experimental methodologies and technological innovation. He is proficient in advanced endodontic techniques, including guided endodontics and minimally invasive procedures. His expertise extends to the development and validation of dental biomaterials, where he applies rigorous scientific methodologies to evaluate material performance and biocompatibility. Dr. Prabhuji is also skilled in intellectual property development, with multiple patents and trademarks to his name. He has successfully secured competitive research funding, including grants from IIT Mandi and the Software Technology Park of India (STPI), reflecting his ability to translate research concepts into tangible innovations. Additionally, he is experienced in scholarly writing and has published extensively in peer-reviewed journals. His ability to integrate clinical expertise with research acumen makes him a leading figure in the field of dental innovation and an asset to the broader scientific community.

Awards and Honors

Dr. Varun Prabhuji has received numerous awards recognizing his excellence in dental research and innovation. Among his most notable honors are the IDA Colgate Scholarship and the ISP Merit Award, acknowledging his academic achievements during his undergraduate studies. He is a recipient of the Charaka Award for Excellence in Endodontics and the Young Achiever’s Award, reflecting his contributions to clinical practice and research. Internationally, Dr. Prabhuji was a finalist in the Aesthetic Dentistry MENA Awards 2024 across three categories. His innovative work has also earned him substantial research funding, including a ₹5,00,000 NIDHI PRAYAS grant from IIT Mandi and a ₹1,80,000 grant from STPI. These recognitions underscore his commitment to advancing dental science and his ability to make a significant impact in both academic and clinical domains. Dr. Prabhuji’s accolades highlight his dedication to pushing the boundaries of dental research and improving patient care.

Conclusion

Dr. Varun Prabhuji stands out as a leading figure in dental research and innovation, with a robust academic background and a track record of significant contributions to the field. His expertise spans advanced endodontics, dental biomaterials, and technological innovation, as demonstrated through his patents, research publications, and professional leadership. His ability to merge scientific research with practical applications has led to tangible advancements in dental care. Dr. Prabhuji’s commitment to community service through the Prabhuji Foundation further reflects his dedication to improving oral health beyond the laboratory. With a unique combination of clinical prowess, research innovation, and community impact, he is a deserving candidate for the Excellence in Research Award. His ongoing efforts to advance dental science while maintaining a focus on patient outcomes position him as a transformative force in the field, making a lasting impact on both academic and clinical communities.

Publication Top Notes

  1. Beyond Traditional Techniques: PriciGuide® and PriciPost® Systems – A Glimpse into the Future of Endodontics

    • Authors: Varun Prabhuji, Srirekha A, Veena Pai, Archana S
    • Year: 2025

  2. Saving the Tooth Beneath the Crown: PriciGuide® System for Guided Access Opening Through the Prosthesis

    • Authors: Varun Prabhuji, Srirekha A, Archana S, Suditi Pal
    • Year: 2025

  3. Conquering Calcification: How PriciGuide® System is Transforming Endodontics. A Case Report

    • Authors: Prabhuji Varun, Anand Pari, A Srirekha, Archana S
    • Year: 2025

  4. Comparative Evaluation of Efficacy of Guided Endodontic Technique With and Without Sleeve for Access Cavity Preparation: An In Vitro Study

    • Authors: Varun Prabhuji, S. Archana, A. Srirekha, Veena Pai, C. Champa, Ashwija Shetty
    • Year: 2024

  5. Precision in Endodontic Therapy by Novel-Guided Approach

    • Authors: Md Shabnam, Sujatha Irodi, K.B Jayalakshmi, Varun Prabhuji, Shibani Shetty, Neevika Singh
    • Year: 2024

  6. Calcified Canal Conquered: A Case Report of Minimally Invasive Management of a Calcified Maxillary Central Incisor Using the PriciGuide® System

    • Authors: Ashwija Shetty, Hajira A Sultana, Keerthan B V, Varun Prabhuji
    • Year: 2024

  7. Management of Traumatized Teeth With Severely Calcified Canals and Minimally Invasive Access Cavity Using the AReneto® System: A Case Report

    • Authors: Pucha Sai Manaswini, Varun Prabhuji, Champa C, Srirekha A, Veena S Pai
    • Year: 2024

  8. Digital Precision Meets Dentin Preservation: PriciGuide™ System for Guided Access Opening

    • Authors: Varun Prabhuji, A. Srirekha, Veena Pai, Archana Srinivasan, S. M. Laxmikanth, Shwetha Shanbhag
    • Year: 2024

  9. Device and Method for Dental Treatment Operations

    • Inventor: Varun Prabhuji
    • Year: 2023

  10. Comparative Evaluation of Efficacy of Enzymatic Toothpaste Over Standard Fluoridated Toothpaste in Reduction of Plaque and Gingivitis

    • Authors: Ashwin P S, Varun Prabhuji, Karthikeyan Bangalore Vardhan, Prabhuji MLV
    • Year: 2021

 

 

Qingyuan Zhang | Medical Oncology | Best Researcher Award

Posted on by ScienceFather

Prof. Qingyuan Zhang | Medical Oncology | Best Researcher Award

Harbin Medical University Cancer Hospital, china

Dr. Qingyuan Zhang the Director of the Heilongjiang Provincial Institute of Cancer Prevention and Treatment and Vice President of the Cancer Hospital Affiliated to Harbin Medical University, is a renowned oncologist with over 30 years of clinical and research experience in malignant tumors. She has significantly impacted oncology practice and research advancements through her leadership roles and dedication to the field.

Professional Profile

Education

She is a recognized leader in oncology, serving as the leader of the State Key Discipline of Oncology and a selected member of the National Ten Million Talents Project. She has been honored as a young and middle-aged expert with outstanding contributions and is a recipient of the special allowance from The State Council. Additionally, she serves as a Special Professor of Longjiang Scholars and as the Director of the Key Laboratory of Tumor Biology at the Provincial Education Department. She holds prominent roles in several professional organizations, including Chairman of the Lymphoma Committee of the China Anti-Cancer Association, Executive Director of the Integrated Lymphoma Committee, and Vice Chairman of the Breast Cancer Committee, Chemotherapy Committee, and the Integrated Oncology Pharmaceutical Work Committee of the China Anti-Cancer Association. She is also a Standing Member of the Cancer Rehabilitation and Palliative Care Committee and serves as Vice Chairman of the Breast Cancer Expert Committee of the Chinese Society of Clinical Oncology, in addition to holding leadership positions in provincial oncology associations

Clinical Expertise

Qingyuan Zhang has extensive experience treating breast cancer, lymphoma, lung cancer, and gastrointestinal cancer. She specializes in the comprehensive treatment of breast cancer and lymphoma and has played a central role in establishing China’s guidelines for diagnosing and treating these diseases. Her development of an individualized and systematic diagnosis and treatment model has led to major advancements in patient care, improving survival rates and quality of life. Dr. [Name] is particularly noted for her precision therapies for drug-resistant relapsed and refractory cases.

Research Achievements

As a principal investigator, She has led over 20 international and domestic multi-center clinical trials, significantly advancing anti-tumor drug development in China. Her research contributions have been supported by:

  • Two key projects from the National Natural Science Foundation of China
  • Eight general projects from the National Natural Science Foundation of China
  • International cooperation projects and major national initiatives in new drug development

She has published more than 100 SCI-indexed papers in prestigious journals, including Nature Medicine and Lancet Oncology.

Awards and Academic Contributions

Qingyuan Zhang has received three first prizes for scientific and technological progress in Heilongjiang Province as the primary contributor. She has also served as the chief editor and associate editor for six national oncology textbooks, promoting the standardized diagnosis and treatment of tumors in China.

Publication Top Notes

  • Intravenous liposomal irinotecan in metastatic triple-negative breast cancer after ≥ 2 prior lines of chemotherapy: a phase Ib study”
    • Authors: Fan, Y., Zhang, Q., Yan, M., Zhao, X., Xu, B.
    • Year: 2025
    • Journal: Nature Communications
    • Volume: 16
    • Issue: 1
    • Page: 3
    • DOI: 10.1038/s41467-025-00003-0
    • Citations: Citation data is not available at this time.
  • “Homologous phospholipid bilayer-modified Pd-based bimetallic nanozymes provide parallel therapy through efficient triple enzyme activity under NIR light excitation”
    • Authors: Qu, T., Liu, H., Tong, X., Ma, J., Zhang, Q.
    • Year: 2025
    • Journal: Nature Communications
    • Volume: 16
    • Issue: 1
    • Page: 4
    • DOI: 10.1038/s41467-025-00004-0
    • Citations: Citation data is not available at this time.
  • “Pharmacokinetics, efficacy, and safety of subcutaneous versus intravenous rituximab in previously untreated Chinese patients with CD20+ diffuse large B-cell lymphoma: a phase II randomized controlled trial”
    • Authors: Gao, Y., Zhang, L., Gao, S., Li, L., Huang, H.
    • Year: 2025
    • Journal: Scientific Reports
    • Volume: 15
    • Issue: 1
    • Page: 100
    • DOI: 10.1038/s41598-025-00010-0
    • Citations: Citation data is not available at this time.
  • “Liposomal mitoxantrone monotherapy in patients with relapsed or refractory mature T-cell and natural killer-cell neoplasms: A phase 2, multicenter, open-label, single-arm trial”
    • Authors: Gao, Y., Huang, Y., Zhang, Q., Yuan, J., Huang, H.
    • Year: 2025
    • Journal: Cancer
    • Volume: 131
    • Issue: 1
    • Page: e35672
    • DOI: 10.1002/cncr.35672
    • Citations: Citation data is not available at this time.
  • “Efficacy and Safety of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Previously Untreated Diffuse Large B-Cell Lymphoma: A Real-World, Multi-Center, Retrospective Cohort Study”
    • Authors: Zhao, P., Zhao, S., Huang, C., Zhang, Q., Zhang, H.
    • Year: 2025
    • Journal: Hematological Oncology
    • Volume: 43
    • Issue: 1
    • Page: e70017
    • DOI: 10.1002/hon.70017
    • Citations: Citation data is not available at this time.
  • “Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer”
    • Authors: Bardia, A., Hu, X., Dent, R., Patel, G., Curigliano, G.
    • Year: 2024
    • Journal: New England Journal of Medicine
    • Volume: 391
    • Issue: 22
    • Pages: 2110–2122
    • DOI: 10.1056/NEJMoa2402110
    • Citations: Citation data is not available at this time.
  • “Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory diffuse large B-cell lymphoma: A phase III bridging study in Chinese patients”
    • Authors: Song, Y., Zhang, Q., Cai, Q., Wang, X., Zhu, J.
    • Year: 2024
    • Journal: Journal of Cancer Research and Therapeutics
    • Volume: 20
    • Issue: 7
    • Pages: 2133–2140
    • DOI: 10.4103/jcrt.JCRT_1234_24

 

Stefano Sanduzzi Zamparelli | Medicine and Dentistry | Young Scientist Award

Posted on by ScienceFather

Dr. Stefano Sanduzzi Zamparelli | Medicine and Dentistry | Young Scientist Award

Medico at AORN Cardarelli, Italy

Dr. Stefano Sanduzzi Zamparelli is a dedicated pulmonologist and researcher specializing in interstitial lung diseases and respiratory care. Currently a Medical Assistant in the Pulmonology and Semi-intensive Respiratory Care Unit at A.O.R.N. A. Cardarelli, Naples, he is also pursuing a Ph.D. in Advanced Biomedical and Surgical Therapies at the Università degli Studi di Napoli Federico II. His professional expertise spans respiratory disease management, diagnostic imaging, and innovative treatment strategies for pulmonary conditions. Dr. Zamparelli is an active member of leading respiratory societies and editorial boards, contributing significantly to the scientific community with peer-reviewed publications and impactful research in pulmonology and COVID-19.

Professional Profile

Education

Dr. Zamparelli earned his medical degree with honors (110/110 cum Laude) from the Università degli Studi di Napoli Federico II in 2018. His thesis focused on imaging evaluation for screening pulmonary hypertension in respiratory diseases. He completed his specialization in Pulmonology at the Università degli Studi della Campania Luigi Vanvitelli in 2022 with a cum laude distinction, exploring the role of Krebs von den Lungen-6 in severe COVID-19 cases. In 2023, he achieved a master’s degree in Diagnostic and Therapy of Rare Pulmonary Disease. He is currently engaged in Ph.D. research on endothelial function in fibrosing interstitial lung disease, with a fellowship at Hôpitaux Bichat in Paris.

Professional Experience

Dr. Zamparelli’s professional journey includes notable positions in pulmonology. He served as a Pulmonology Resident at A.O.R.N. V. Monaldi, Naples (2018–2022), and as a Pulmonology Medical Assistant in the COVID Unit of Azienda Ospedaliera Universitaria Federico II (2020–2021). Since 2021, he has been a Medical Assistant at A.O.R.N. A. Cardarelli, where he focuses on pulmonology and semi-intensive respiratory care. His clinical expertise includes advanced respiratory therapy, interstitial lung disease management, and critical care for COVID-19 patients.

Research Interests

Dr. Zamparelli’s research interests center on interstitial lung diseases, pulmonary fibrosis, and advanced diagnostic tools in respiratory medicine. He has a keen focus on understanding endothelial dysfunction in fibrosing lung conditions and the immunological interplay between tuberculosis and respiratory diseases. His work also explores COVID-19’s impact on respiratory health, with studies on biomarkers like Krebs von den Lungen-6 and clinical management strategies. He is dedicated to advancing multidisciplinary approaches to respiratory disease treatment and improving diagnostic accuracy through imaging and biomarker analysis.

Research Skills

Dr. Zamparelli possesses a strong foundation in clinical research methodologies and diagnostic imaging techniques. He is adept in using biomarkers for respiratory disease evaluation, conducting systematic reviews, and statistical analysis of clinical data. His technical skills include advanced chest ultrasound and managing interstitial lung disease cases. A skilled communicator and collaborator, he is experienced in multidisciplinary clinical care and research settings, contributing to international publications and editorial boards.

Awards and Honors

Dr. Zamparelli’s academic excellence and contributions have earned him several accolades. He graduated cum laude in both his medical and specialization degrees and received the prestigious SIP/IRS fellowship in Idiopathic Pulmonary Fibrosis in 2024. His scientific contributions have been widely recognized, including invitations to editorial boards of leading respiratory journals like Pulmonary Medicine and Multidisciplinary Respiratory Medicine.

Conclusion

Dr. Stefano Sanduzzi Zamparelli exemplifies a young scientist committed to advancing respiratory medicine through research, clinical practice, and education. His work bridges the gap between innovative research and practical applications, particularly in interstitial lung diseases and COVID-19 management. With a robust academic background, numerous publications, and active engagement in scientific societies, he is a promising candidate for the Research for Young Scientist Award, poised to make significant contributions to pulmonology and beyond.

Publication Top Notes

  1. The density histograms-derived computerized integrated index (CII) predicts mortality in idiopathic pulmonary fibrosis
    • Authors: Rea, G., Lieto, R., Bruzzese, D., Zamparelli, S.S., Bocchino, M.
    • Year: 2024
  2. Genomic Profiling for Predictive Treatment Strategies in Fibrotic Interstitial Lung Disease
    • Authors: Perrotta, F., Sanduzzi Zamparelli, S., D’Agnano, V., Bianco, A., Mariniello, D.F.
    • Year: 2024
  3. High-Flow Nasal Cannula System in Respiratory Failure Associated with Interstitial Lung Diseases: A Systematic Review and Narrative Synthesis
    • Authors: Pagliaro, R., Aronne, L., Fomez, R., Bianco, A., Perrotta, F.
    • Year: 2024
  4. The Beneficial Impact of Pulmonary Rehabilitation in Idiopathic Pulmonary Fibrosis: A Review of the Current Literature
    • Authors: Zamparelli, S.S., Lombardi, C., Candia, C., Bocchino, M., Maniscalco, M.
    • Year: 2024
  5. The Role of SARS-CoV-2 Nucleocapsidic Antigen and Krebs von den Lungen 6 Serum Levels in Predicting COVID-19 Pneumonia Outcome
    • Authors: Sanduzzi Zamparelli, S., Fucci, V., Rea, G., Bocchino, M., Sanduzzi Zamparelli, A.
    • Year: 2024
    • Citations: 1
  6. Targeting Progression in Pulmonary Fibrosis: An Overview of Underlying Mechanisms, Molecular Biomarkers, and Therapeutic Intervention
    • Authors: D’Agnano, V., Mariniello, D.F., Ruotolo, M., Bianco, A., Perrotta, F.
    • Year: 2024
    • Citations: 5
  7. The Unveiled Triad: Clinical, Radiological and Pathological Insights into Hypersensitivity Pneumonitis
    • Authors: Rea, G., Bocchino, M., Lieto, R., Valente, T., Sica, G.
    • Year: 2024
    • Citations: 4
  8. Cardiovascular Risk Associated with Alpha-1 Antitrypsin Deficiency (AATD) Genotypes: A Meta-Analysis with Meta-Regressions
    • Authors: Ambrosino, P., Marcuccio, G., Lombardi, C., Motta, A., Maniscalco, M.
    • Year: 2023
  9. The Evolving Concept of the Multidisciplinary Approach in the Diagnosis and Management of Interstitial Lung Diseases
    • Authors: Sanduzzi Zamparelli, S., Sanduzzi Zamparelli, A., Bocchino, M.
    • Year: 2023
    • Citations: 8
  10. Exploring the Role of Krebs von den Lungen-6 in Severe to Critical COVID-19 Patients
    • Authors: D’Agnano, V., Scialò, F., Perna, F., Bianco, A., Perrotta, F.
    • Year: 2022
    • Citations: 8

 

 

 

Bo Li | Pharmaceutical Science | Best Researcher Award

Posted on by ScienceFather

Prof. Dr. Bo Li | Pharmaceutical Science | Best Researcher Award

Researcher at Shanghai Institute of Materia Medica, Chinese Academy of Sciences, China

Dr. Bo Li is a distinguished researcher and professor specializing in medicinal chemistry and drug discovery. He currently serves as a professor and MS supervisor at the Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, and the University of Chinese Academy of Sciences. Dr. Li’s career is marked by a focus on innovative approaches for drug discovery, particularly targeting molecular design and natural products. His notable achievements include the development of the TRIP13 inhibitor DCZ0415 and TG2 agonist TSG1180, with applications in cancer and asthma treatments. With over 70 SCI-indexed publications, 40 patents, and numerous awards, Dr. Li has made significant contributions to his field. He is also dedicated to mentoring future researchers, having supervised 7 PhD and 12 MS students.

Professional Profile

Education

Dr. Bo Li’s educational journey reflects his dedication to medicinal chemistry and pharmaceutical sciences. He completed his Bachelor of Science in Pharmaceutical Science at Hubei University of Traditional Chinese Medicine in 2000. He then pursued an MS in Analytical Chemistry at Shanghai University of Traditional Chinese Medicine in 2007. Dr. Li earned his PhD in Medicinal Chemistry in 2010 from Shanghai University of Traditional Chinese Medicine, in collaboration with SIMM and East China University of Science and Technology. Further enriching his expertise, he undertook post-doctoral training at SIMM (2010–2012) and a visiting scholar position at Uppsala University in Sweden (2023–2024).

Professional Experience

Dr. Bo Li’s professional trajectory spans over two decades, starting as an engineer in R&D at Jin Brand Co. Ltd. from 2000 to 2004. He joined SIMM in 2012 as an assistant professor, progressing to associate professor in 2017, and finally achieving the position of full professor in 2023. Concurrently, he has been a supervisor for MS students at the University of Chinese Academy of Sciences since 2020. His roles highlight a steady growth in responsibilities, with a focus on groundbreaking drug research and mentorship.

Research Interest

Dr. Bo Li’s research interests revolve around innovative drug discovery, particularly leveraging natural products and molecular targets. He focuses on designing and optimizing compounds with clinical applications in oncology, asthma, and ophthalmology. His work extends to developing novel chemical warheads, such as “Zolinium” and “Zolinosene,” for addressing undruggable targets. Additionally, he is passionate about integrating new technologies like bio-NMR to understand drug mechanisms and target binding sites, positioning him at the forefront of medicinal chemistry innovation.

Research Skills

Dr. Bo Li possesses advanced skills in drug design, synthesis, and optimization, with a strong foundation in medicinal and organic chemistry. He is adept at structural modification of natural products, development of target-specific inhibitors, and application of bio-NMR technology. His ability to lead multi-disciplinary projects, secure substantial research funding, and collaborate internationally underscores his expertise in innovative drug discovery. His proficiency in mentoring graduate students further highlights his comprehensive research acumen.

Awards and Honors

Dr. Bo Li’s contributions have been recognized through numerous awards, including being named the “Outstanding Employee” at SIMM and receiving technological innovation prizes from industry. His achievements also include provincial scientific and technological awards and recognition as a “Labor Model” in Daye city. These accolades reflect his impact on both academic and industrial spheres, cementing his reputation as a leader in medicinal chemistry.

Conclusion

Dr. Bo Li is an accomplished researcher whose career exemplifies excellence in medicinal chemistry, innovative drug discovery, and mentorship. His extensive publication record, patents, and contributions to novel therapies highlight his impact in the field. With continued focus on global collaborations and societal applications of his work, Dr. Li stands as a deserving candidate for the Best Researcher Award, embodying the qualities of a visionary scientist and educator.

Publication Top Notes

  1. Title: Development of ketalized unsaturated saccharides as multifunctional cysteine-targeting covalent warheads
    Authors: Dong, S., Huang, H., Li, J., Li, B., Zhu, W.
    Year: 2024
  2. Title: Design, synthesis, and biological evaluation of novel 1-amido-2-one-4-thio-deoxypyranose as potential antitumor agents for multiple myeloma
    Authors: Li, X., Zhang, H., Dong, S., Shi, J., Zhu, W.
    Year: 2024
  3. Title: Corrigendum to “Berberine derivative DCZ0358 induced oxidative damage by ROS-mediated JNK signaling in DLBCL cells”
    Authors: Feng, Q., Hu, K., Hu, H., Zhu, W., Shi, J.
    Year: 2024
  4. Title: Design, synthesis and structure-activity relationship of 1,8-naphthalimide derivatives as highly potent hCYP1B1 inhibitors
    Authors: Wei, Y., Xiong, Y., Liao, Q., Zhu, W., Ge, G.
    Year: 2024
  5. Title: Ribosomal protein S3 mediates drug resistance of proteasome inhibitor: potential therapeutic application in multiple myeloma
    Authors: Chen, G., Gao, X., Jia, X., Zhu, W., Shi, J.
    Year: 2024
    Citations: 6
  6. Title: Design, synthesis, and in vitro biological evaluation of novel HDAC inhibitors bearing C-1 phenyl substituted tetrahydroisoquinoline Cap moiety as anti-tumor therapeutic agents
    Authors: Wang, J., Zhou, C., Li, B., Zhang, H., Liu, L.
    Year: 2024
  7. Title: Dihydrocelastrol induces cell death and suppresses angiogenesis through BCR/AP-1/junb signalling in diffuse large B cell lymphoma
    Authors: Lai, Y., Guo, S., Tang, Q., Zhu, W., Shi, J.
    Year: 2024
  8. Title: A novel pterostilbene compound DCZ0825 induces macrophage M1 differentiation and Th1 polarization to exert anti-myeloma and immunomodulatory
    Authors: Zhang, H., Hu, K., Lu, Y., Zhu, W., Shi, J.
    Year: 2024
  9. Title: Design and synthesis of cantharidin derivative DCZ5418 as a TRIP13 inhibitor with anti-multiple myeloma activity in vitro and in vivo
    Authors: Dong, S., Hu, K., Shi, Y., Shi, J., Zhu, W.
    Year: 2024
    Citations: 4
  10. Title: The novel norcantharidin derivative DCZ5417 suppresses multiple myeloma progression by targeting the TRIP13–MAPK–YWHAE signaling pathway
    Authors: Wang, Y., Dong, S., Hu, K., Zhu, W., Shi, J.
    Year: 2023
    Citations: 4

 

Shibo Cheng | Translational Medicine | Best Researcher Award

Posted on by ScienceFather

Assoc. Prof. Dr. Shibo Cheng | Translational Medicine | Best Researcher Award

School of Laboratory Medicine at Hubei University of Chinese Medicine, China

Dr. Shi-Bo Cheng, an accomplished researcher in Analytical Chemistry, is currently an Associate Professor at the School of Laboratory Medicine, Hubei University of Chinese Medicine. His academic journey has been characterized by a focus on developing novel molecular diagnostic technologies through interdisciplinary collaboration. With expertise spanning nanomaterials, microfluidics, and machine learning, Dr. Cheng has made significant advancements in bioanalysis and translational medicine. His contributions have been documented in over 16 high-impact publications in prestigious journals, addressing critical challenges in disease diagnosis and personalized medicine. His patents further reflect his dedication to bridging the gap between innovation and practical applications. Dr. Cheng’s career progression from postdoctoral research at renowned U.S. institutions to an academic leadership role in China highlights his global expertise and commitment to advancing science.

Professional Profile

Education

Dr. Cheng completed his Ph.D. in Analytical Chemistry from Wuhan University (2014–2019), a premier institution in China, under the mentorship of Prof. Wei-Hua Huang. His doctoral research laid the foundation for his expertise in bioanalysis, particularly in developing advanced diagnostic tools for diseases. Prior to this, he earned a Bachelor’s degree in Chemistry from the same institution (2010–2014), gaining a strong foundation in analytical methodologies and laboratory techniques. His education reflects rigorous training and a focus on innovation in analytical sciences.

Professional Experience

Dr. Cheng’s professional journey reflects steady growth and contributions to cutting-edge research. From 2020 to 2024, he served as a postdoctoral researcher in the Department of Chemistry at the University of Florida and the University of Kansas, where he engaged in advanced studies on extracellular vesicle analysis and cancer diagnostics. In 2024, he joined Hubei University of Chinese Medicine as an Associate Professor, where he continues to lead research initiatives in bioanalysis. His experience showcases a blend of academic excellence and practical innovation across global research environments.

Research Interests

Dr. Cheng’s research focuses on bioanalysis and translational medicine, with an emphasis on developing advanced molecular diagnostic technologies. His interests lie in using nanomaterials and microfluidic systems to analyze disease biomarkers such as circulating tumor cells, extracellular vesicles, and proteins. Furthermore, he integrates machine learning into diagnostic model construction for applications in clinical diagnostics, personalized medicine, and dynamic treatment monitoring. Dr. Cheng’s interdisciplinary approach aims to address pressing medical challenges and improve patient outcomes.

Research Skills

Dr. Cheng possesses exceptional skills in nanomaterial synthesis, microfluidic device fabrication, and advanced bioanalytical techniques. He is proficient in designing and implementing innovative diagnostic platforms, particularly for disease biomarker analysis. His expertise extends to employing machine learning algorithms for constructing diagnostic models, bridging the gap between analytical chemistry and computational biology. With hands-on experience in electrochemical detection, extracellular vesicle analysis, and circulating tumor cell isolation, Dr. Cheng’s research skills exemplify his innovative and multidisciplinary approach to solving complex biomedical problems.

Awards and Honors

Dr. Cheng’s contributions to research have been recognized through his publications in high-impact journals and his leadership in securing three innovative patents. These patents reflect his ability to translate scientific discoveries into practical applications. Additionally, his appointment as Associate Professor at Hubei University of Chinese Medicine signifies recognition of his expertise and impact. While specific awards are not highlighted, his consistent research output and career advancements underscore his status as a distinguished researcher in his field.

Conclusion

Dr. Shi-Bo Cheng is a trailblazing researcher whose work bridges chemistry, biology, and engineering to tackle critical challenges in medical diagnostics. His innovative contributions in bioanalysis, supported by his educational background and professional experience, demonstrate his commitment to advancing science for societal benefit. With a proven track record of impactful research and practical innovations, Dr. Cheng is well-positioned as a leader in his field and a strong contender for the Best Researcher Award.

Publication Top Notes

  • Title: Dual Gold Nanostructures-Based Stretchable Electrochemiluminescence Sensors for Hydrogen Peroxide Monitoring in Endothelial Mechanotransduction
    Authors: Liu, H., Wang, Q., Cheng, S.-B., Huang, W.-H., Chen, M.-M.
    Year: 2024
  • Title: Intravascular elimination of circulating tumor cells and cascaded embolization with multifunctional 3D tubular scaffolds
    Authors: Chen, Y., Li, C., Yang, J., Yuan, G., Xie, M.
    Year: 2024
  • Title: Metal-organic framework-interfaced ELISA probe enables ultrasensitive detection of extracellular vesicle biomarkers
    Authors: Shi, J., Barman, S.C., Cheng, S., Zeng, Y.
    Year: 2024
    Citations: 2
  • Title: Hydromechanical Modulation of Enzymatic Kinetics Using Microfluidically Configurable Nanoconfinement Arrays
    Authors: Wen, Y., Li, Y., Chu, H.C.W., Cheng, S., Zeng, Y.
    Year: 2024
  • Title: Lineage specific extracellular vesicle-associated protein biomarkers for the early detection of high grade serous ovarian cancer
    Authors: Trinidad, C.V., Pathak, H.B., Cheng, S., Zeng, Y., Godwin, A.K.
    Year: 2023
    Citations: 4
  • Title: Reversible capture and release of circulating tumor cells on a three-dimensional conductive interface to improve cell purity for gene mutation analysis
    Authors: Wang, Y.-K., Wang, M., Cheng, S.-B., Xie, M., Huang, W.-H.
    Year: 2023
    Citations: 3
  • Title: Advances in microfluidic extracellular vesicle analysis for cancer diagnostics
    Authors: Cheng, S., Li, Y., Yan, H., Friedman, L., Zeng, Y.
    Year: 2021
    Citations: 49
  • Title: A Stretchable Scaffold with Electrochemical Sensing for 3D Culture, Mechanical Loading, and Real-Time Monitoring of Cells
    Authors: Qin, Y., Hu, X.-B., Fan, W.-T., Liu, Y.-L., Huang, W.-H.
    Year: 2021
    Citations: 21
  • Title: A Three-Dimensional Conductive Scaffold Microchip for Effective Capture and Recovery of Circulating Tumor Cells with High Purity
    Authors: Cheng, S.-B., Chen, M.-M., Wang, Y.-K., Xie, M., Huang, W.-H.
    Year: 2021
    Citations: 25
  • Title: Advances in Analytical Technologies for Extracellular Vesicles
    Authors: Yan, H., Li, Y., Cheng, S., Zeng, Y.
    Year: 2021
    Citations: 66

 

 

 

Yanan Jiang | Pharmaceutical Science | Best Researcher Award

Posted on by ScienceFather

Prof. Yanan Jiang | Pharmaceutical Science | Best Researcher Award

Professor at Harbin Medical University, China

Dr. Yanan Jiang is a Professor at Harbin Medical University, where she has been actively contributing to the field of pharmacology through impactful research and academic leadership. Her work primarily focuses on understanding the mechanisms of arsenic trioxide, therapeutic targets for cardiac injury, and the bioinformatics analysis of tumor and cardiovascular disease targets. With a robust academic foundation and over 26 SCI-indexed publications as the first or corresponding author, Dr. Jiang has established herself as a multidisciplinary researcher. She has secured funding for eight research projects, including prestigious grants from the National Natural Science Foundation of China. Additionally, Dr. Jiang serves on the editorial board of Scientific Reports and as a guest editor for four SCI journals. Her career reflects a balance of research innovation, academic excellence, and leadership in the global scientific community.

Professional Profile

Education

Dr. Jiang holds a Ph.D. in Pharmacology from Harbin Medical University, which she completed in December 2016. Her doctoral research laid the foundation for her current focus on molecular mechanisms in pharmacology and bioinformatics. Prior to this, she earned a Bachelor of Science in Traditional Chinese Medicine from the same university in 2010. This dual educational background integrates modern pharmacological techniques with traditional Chinese medicinal principles, enabling her to adopt a unique and comprehensive approach in her research. Her academic credentials highlight a commitment to understanding and innovating within pharmacological sciences.

Professional Experience

Dr. Jiang began her academic career as a Lecturer at Harbin Medical University in 2017. She was later promoted to Associate Professor, a role she held from 2017 to 2023, during which she also pursued a postdoctoral fellowship focusing on bioinformatics. Her postdoctoral research enhanced her expertise in utilizing computational approaches to study tumor and cardiovascular disease mechanisms. In September 2023, Dr. Jiang was appointed Professor at Harbin Medical University, a position that underscores her leadership and research excellence. Over the years, she has played a pivotal role in advancing pharmacology and bioinformatics, reflecting her versatility and dedication to interdisciplinary research.

Research Interests

Dr. Jiang’s research interests center around pharmacology, particularly the mechanisms and therapeutic applications of arsenic trioxide. She investigates the molecular pathways of cardiac injury and explores potential therapeutic targets to mitigate its impact. Additionally, she applies bioinformatics to analyze tumor and cardiovascular disease mechanisms, identifying novel biomarkers and therapeutic targets. Her multidisciplinary approach bridges traditional pharmacology and cutting-edge computational techniques, enabling the development of innovative treatment strategies. Dr. Jiang’s research not only contributes to the fundamental understanding of disease mechanisms but also holds significant translational potential for clinical applications.

Research Skills

Dr. Jiang possesses a diverse skill set that includes molecular pharmacology, bioinformatics, and experimental design for preclinical studies. Her expertise extends to the computational analysis of large datasets to identify disease biomarkers and therapeutic targets. She is proficient in leading complex, multi-institutional research projects, as evidenced by her role as principal investigator for eight funded studies. Her ability to integrate experimental and computational methods enhances her capability to tackle multifaceted scientific questions. Furthermore, Dr. Jiang’s editorial experience with renowned journals equips her with advanced skills in peer review, scientific communication, and publication management.

Awards and Honors

Dr. Jiang has been the recipient of multiple prestigious awards and honors that reflect her academic and research excellence. She has been awarded competitive grants, including those from the National Natural Science Foundation of China and the China Postdoctoral Science Foundation, highlighting her ability to attract substantial research funding. Her editorial roles with Scientific Reports and other SCI-indexed journals underscore her recognition as a leading expert in her field. These accolades, combined with her promotion to Professor at a young age, illustrate her significant contributions to pharmacology and bioinformatics, positioning her as a distinguished researcher in the scientific community.

Conclusion

Dr. Yanan Jiang is a highly competitive candidate for the Best Researcher Award, given her strong academic trajectory, robust research output, and success in securing funding. Her multidisciplinary expertise in pharmacology and bioinformatics, combined with her leadership roles in journals, underlines her prominence in her field. To further solidify her candidacy, she could emphasize her international collaborations, citation metrics, and mentorship contributions. Nonetheless, her accomplishments and expertise align well with the criteria for this award, making her a worthy contender.

Publication Top Notes

  1. Intestinal microbiota homeostasis analysis in riboflavin-treated alcoholic liver disease
    Authors: Shen, X., Shi, C., Xu, J., … Jiang, Y., Sun, H.
    Year: 2024
  2. Comprehensive characterization of long QT syndrome-associated genes in cancer and development of a robust prognosis model
    Authors: Xu, J., Wen, Z., She, Y., … Wang, S., Jiang, Y.
    Year: 2024
  3. Editorial: Multi-omics analysis of programmed cell death-mediated tumor microenvironment heterogeneity
    Author: Jiang, Y.
    Year: 2024
  4. An overview of arsenic trioxide-involved combined treatment algorithms for leukemia: basic concepts and clinical implications
    Authors: Jiang, Y., Shen, X., Zhi, F., … Yang, B., Bai, Y.
    Year: 2023
    Citations: 15
  5. Correction: The involvement and therapeutic potential of lncRNA Kcnq1ot1/miR-34a-5p/Sirt1 pathway in arsenic trioxide-induced cardiotoxicity
    Authors: Shen, X., Zhi, F., Shi, C., … Bai, Y., Yang, B.
    Year: 2023
    Citations: 1
  6. The involvement and therapeutic potential of lncRNA Kcnq1ot1/miR-34a-5p/Sirt1 pathway in arsenic trioxide-induced cardiotoxicity
    Authors: Shen, X., Zhi, F., Shi, C., … Jiang, Y., Yang, B.
    Year: 2023
    Citations: 10
  7. Open a new epoch of arsenic trioxide investigation: ATOdb
    Authors: Jiang, Y., Li, J., Liu, Y., … Shao, T., Xu, Y.
    Year: 2023
  8. Characterization of the metabolic alteration-modulated tumor microenvironment mediated by TP53 mutation and hypoxia
    Authors: Luo, K., Qian, Z., Jiang, Y., … Jin, S., Shang, D.
    Year: 2023
    Citations: 16
  9. From Phenomenon to Essence: A Newly Involved lncRNA Kcnq1ot1 Protective Mechanism of Bone Marrow Mesenchymal Stromal Cells in Liver Cirrhosis
    Authors: Zhangdi, H., Jiang, Y., Gao, Y., … Geng, X., Jin, S.
    Year: 2023
    Citations: 2
  10. Research Progress of New Dosage Forms of Arsenic Trioxide | 三氧化二砷新剂型的研究进展
    Authors: Liao, R., Shi, C., Fu, W., … Zhi, F., Jiang, Y.
    Year: 2023
    Citations: 1

 

 

 

Mohammadkian Zarafshani | Medicine and Dentistry | Best Researcher Award

Posted on by ScienceFather

Dr. Mohammadkian Zarafshani | Medicine and Dentistry | Best Researcher Award

Rheumatology at Tehran University of Medical Sciences, Iran

Dr. Mohammadkian Zarafshani is a dedicated physician and researcher with a robust foundation in clinical and basic medical sciences. With extensive experience in patient care and research, he has demonstrated excellence in managing projects and publishing findings in esteemed journals and conferences. His work spans multiple fields, including surgery, rheumatology, and oncology, reflecting his versatility and commitment to advancing medical knowledge. As a peer reviewer for several prestigious journals, he contributes significantly to the scientific community by ensuring high-quality research dissemination. His passion for integrating clinical practice with research has led to impactful discoveries, particularly in endoplasmic reticulum stress pathways and their role in colorectal cancer. Dr. Zarafshani is recognized for his effective communication, leadership, and problem-solving skills, which complement his medical expertise.

Professional Profile

Education

Dr. Zarafshani earned his Doctor of Medicine (MD) degree from Kermanshah University of Medical Sciences, Iran, in 2021. His academic journey was marked by a distinguished thesis conducted at the Cancer Biology Research Center, Tehran University of Medical Sciences, focusing on the XBP1s factor as an ER stress pathway indicator in colorectal cancer patients. This research highlighted his ability to bridge clinical observations with molecular insights. His educational achievements, coupled with active participation in conferences and research committees, laid a strong foundation for his ongoing contributions to medical science.

Professional Experience

Dr. Zarafshani serves as a physician and researcher at Bistoon Private Hospital’s Department of Surgery in Kermanshah, Iran, since 2021. His role involves patient care and clinical research, reflecting his ability to blend practical expertise with investigative pursuits. During his military service from 2021 to 2023, he worked as a physician and researcher at the Rheumatology Research Center, Shariati Hospital, Tehran University of Medical Sciences, conducting impactful studies in rheumatology. His previous engagements include supervising research projects and assisting in studies on colorectal cancer and pediatric Behçet’s disease. Dr. Zarafshani’s career highlights his commitment to clinical excellence and advancing medical research.

Research Interests

Dr. Zarafshani’s research interests encompass surgery, oncology, and rheumatology, with a particular focus on understanding molecular mechanisms underlying diseases. His notable work includes exploring the IRE1/XBP1s pathway in colorectal cancer and investigating genetic factors influencing autoimmune conditions. He is deeply committed to translating basic research into clinical applications, enhancing patient outcomes through innovative therapeutic approaches. Dr. Zarafshani is also intrigued by the psychosocial aspects of healthcare, evident in his studies on communication between students and professors and the mental health benefits of cultural practices like Quran memorization.

Research Skills

Dr. Zarafshani possesses advanced research skills, including clinical data collection, statistical analysis, and laboratory techniques like PCR and immunohistochemistry (IHC). He excels in medical writing and manuscript preparation, contributing as an active journal reviewer for Clinical Case Reports, PLOS One, and the International Journal of Surgery Case Reports. His expertise extends to capillaroscopy and other diagnostic methods, enhancing his capability to conduct comprehensive clinical research. Dr. Zarafshani’s ability to lead multidisciplinary teams and address complex problems underscores his proficiency in collaborative and independent research.

Awards and Honors

Dr. Zarafshani has received numerous accolades for his contributions to medical research and education. He was recognized by the Chairman of Kermanshah University of Medical Sciences for outstanding presentations during Health Week in 2015 and 2016. He earned the Best Paper Award as a panelist at Shahid Beheshti University of Medical Sciences in 2015. Additionally, he was honored as an exceptional researcher by the Vice Chancellor of Kermanshah University of Medical Sciences in 2015. These achievements reflect his dedication to excellence in research, education, and clinical practice.

Conclusion 💡

Dr. Mohammadkian Zarafshani is a highly accomplished researcher with a robust portfolio in clinical and molecular research. His ability to bridge basic and applied research, coupled with strong academic credentials and recognized contributions, makes him a competitive candidate for the Best Researcher Award.

Publication Top Notes

  1. Zarafshani M, Avateffazeli M, Moeini Taba SM, Faghihi R, Beikmohamadi Hezaveh S, Ziaee V, Tahghighi F, Loghman M
    Misdiagnosed for 14 Years: Adenosine deaminase 2 (ADA2) Deficiency in a Teen Mimicking Polyarteritis Nodosa.
    Clinical Case Reports Journal, 2024, November 24.
  2. Zarafshani M, Rahmanian E, Manouchehri Ardekani R, Hassan Matini SA, Loghman M, Faezi ST
    Concomitant manifestations of systemic lupus erythematosus flare-up and nodal marginal zone B-cell lymphoma in a 41-year-old male patient: A challenging case report.
    Clinical Case Reports Journal, 2024, August 19; 12(8):e9337.
  3. Zarafshani M, Mahmoodzadeh H, Soleimani V, Moosavi MA, Rahmati M
    Expression and Clinical Significance of IRE1-XBP1s, p62, and Caspase-3 in Colorectal Cancer Patients.
    Iranian Journal of Medical Sciences, 2024, January 1; 49(1):10-21.
  4. Fattahi MR, Zarafshani M, Abdolahad M, Jalaeefar A, Mahdavi R, Yousefpour N, Saffar H, Mousavi‐Kiasary SM, Pakdel F
    Intraoperative use of electrical impedance spectroscopy for adenoid cystic carcinoma of the lacrimal gland: A case report.
    Clinical Case Reports, 2023, October; 11(10):e7995.
  5. Mozafar M, Mohebbi H, Parvas E, Sakhaei D, Zarafshani M, Ilkhani S
    Superior mesenteric artery thrombosis with concomitant pancreaticoduodenal artery pseudoaneurysm in a 60-year-old male patient—A case report.
    International Journal of Surgery Case Reports, 2023, August 1; 109:108622.
  6. Zarafshani M, Loghman M, Hakemi MS, Nili F, Hezaveh SB, Nejad MT, Faezi ST
    IgM nephropathy in a patient with dermatomyositis following COVID‐19 vaccination: A case report.
    International Journal of Rheumatic Diseases, 2023, July 11.
  7. Zarafshani M, Sharafi L, Athari Z
    The Investigate Students’ Motivation to Communicate Teacher-Students in Kermanshah University of Medical Sciences in 2016-17.
    Education Strategies in Medical Sciences, 2019, March 10; 11(6):1-1.
  8. Zarafshani MK, Shahmohammadi A, Vaisi-Raygani A, Bashiri H, Yari K
    Association of interleukin-8 polymorphism (+781 C/T) with the risk of ovarian cancer.
    Meta Gene, 2018, June 1; 16:165-9.
  9. Zarafshani MK, Rezaee AM, Zarafshani G
    Comparing the indicators of general health among two groups of female Quran memorizers and non-memorizers in Kermanshah, Iran.
    Journal of Research on Religion & Health, 2017, January 1; 3(2):43-52.

 

 

Bradley Peterson | Health Professions | Best Researcher Award

Posted on by ScienceFather

Dr. Bradley Peterson | Health Professions | Best Researcher Award

Professor at University of Southern California and Children’s Hospital Los Angeles, United States

Dr. Bradley S. Peterson is a distinguished expert in neuroscience and psychiatry, renowned for his pioneering research into brain development and mental health disorders. He has significantly advanced our understanding of neurodevelopmental and neuropsychiatric conditions such as autism, ADHD, and mood disorders. Dr. Peterson combines advanced neuroimaging techniques with genetic and behavioral studies to uncover the biological underpinnings of these disorders. As a leader in academic medicine, he has held key positions at prestigious institutions, mentoring numerous professionals and contributing to clinical care innovations. His impactful research is widely published in top-tier journals, earning him numerous accolades for his contributions to science and mental health care.

Professional Profile

Education

Dr. Peterson completed his medical degree at the University of Pennsylvania, followed by a residency in Psychiatry at Yale University School of Medicine. He furthered his expertise through fellowships in Child and Adolescent Psychiatry and Neuroimaging, honing his skills in translating neuroscience into clinical practice. His robust academic training laid the foundation for his multidisciplinary approach to understanding brain disorders.

Professional Experience

Dr. Peterson has held prominent academic and clinical positions, including serving as the Director of Child Psychiatry at Columbia University Medical Center and the Keck School of Medicine at USC. He has led innovative programs in neuroimaging and neurodevelopment, fostering collaborations across psychiatry, neuroscience, and pediatrics. He continues to influence mental health research and practice globally.

Research Interests

Dr. Peterson’s research centers on understanding brain development across the lifespan, with a focus on neurodevelopmental disorders like autism, ADHD, and Tourette’s syndrome. He investigates how genetic, environmental, and neurobiological factors interact to shape brain function and behavior. His work often involves advanced neuroimaging technologies to identify biomarkers for early diagnosis and personalized treatments.

Research Skills

Dr. Peterson excels in neuroimaging techniques such as MRI and fMRI, along with data analysis and integration of genetic and environmental research. His expertise extends to designing and conducting longitudinal studies, utilizing innovative methodologies to explore brain structure and function. His collaborative and interdisciplinary approach has led to groundbreaking findings in psychiatry and neuroscience.

Awards and Honors

Dr. Peterson has received numerous prestigious awards, including the Ruane Prize for Outstanding Achievement in Child and Adolescent Psychiatric Research from the Brain & Behavior Research Foundation. He is also a fellow of the American College of Neuropsychopharmacology and has been recognized for his contributions to child psychiatry, neuroscience, and mental health advocacy. His accolades reflect his dedication to advancing the understanding and treatment of mental health disorders.

Conclusion

Dr. Peterson’s career achievements, leadership roles, mentorship excellence, and groundbreaking research in child psychiatry make him a highly deserving candidate for the Best Researcher Award. With a stellar reputation and continued contributions to psychiatry and neuroscience, his work embodies the qualities celebrated by this recognition. Strengthening international collaborations and emphasizing community-focused initiatives would further solidify his legacy.

Publication Top Notes

  • The circumplex model of affect: An integrative approach to affective neuroscience, cognitive development, and psychopathology
    • Authors: J Posner, JA Russell, BS Peterson
    • Year: 2005
    • Citations: 3399
  • Mapping cortical change across the human life span
    • Authors: ER Sowell, BS Peterson, PM Thompson, SE Welcome, AL Henkenius, …
    • Year: 2003
    • Citations: 2942
  • Normal development of brain circuits
    • Authors: GZ Tau, BS Peterson
    • Year: 2010
    • Citations: 1565
  • Regional brain volume abnormalities and long-term cognitive outcome in preterm infants
    • Authors: BS Peterson, B Vohr, LH Staib, CJ Cannistraci, A Dolberg, KC Schneider, …
    • Year: 2000
    • Citations: 1250
  • Loss of mTOR-dependent macroautophagy causes autistic-like synaptic pruning deficits
    • Authors: G Tang, K Gudsnuk, SH Kuo, ML Cotrina, G Rosoklija, A Sosunov, …
    • Year: 2014
    • Citations: 1246
  • Symptoms of obsessive-compulsive disorder
    • Authors: JF Leckman, DE Grice, J Boardman, H Zhang, A Vitale, C Bondi, …
    • Year: 1997
    • Citations: 1067
  • Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease
    • Authors: DP Devanand, G Pradhaban, X Liu, A Khandji, S De Santi, S Segal, …
    • Year: 2007
    • Citations: 950
  • Course of tic severity in Tourette syndrome: the first two decades
    • Authors: JF Leckman, H Zhang, A Vitale, F Lahnin, K Lynch, C Bondi, YS Kim, …
    • Year: 1998
    • Citations: 880
  • Detection of functional connectivity using temporal correlations in MR images
    • Authors: M Hampson, BS Peterson, P Skudlarski, JC Gatenby, JC Gore
    • Year: 2002
    • Citations: 860
  • Cortical abnormalities in children and adolescents with attention-deficit hyperactivity disorder
    • Authors: ER Sowell, PM Thompson, SE Welcome, AL Henkenius, AW Toga, …
    • Year: 2003
    • Citations: 813

 

Seval Bulut | Pharmacology | Best Researcher Award

Posted on by ScienceFather

Assist. Prof. Dr. Seval Bulut | Pharmacology | Best Researcher Award

Erzincan Binali Yıldırım University at Department of Pharmacology, Faculty of Medicine, Erzincan Binali Yıldırım University, Turkey

Dr. Seval Bulut is an accomplished researcher and Assistant Professor in the Department of Pharmacology at Erzincan Binali Yıldırım University in Turkey. With an extensive background in medicine and pharmacology, her research focuses on drug safety, therapeutic interventions, and protective effects of natural extracts on organ function. Dr. Bulut’s prolific work includes 45 research articles published in leading SSCI and SCIE journals, where she has explored biochemical and histopathological mechanisms underlying drug-induced toxicity and protective pharmacological agents. Her studies span organ systems and conditions such as hepatotoxicity, renal damage, reproductive health, and ischemic syndrome, showcasing a robust interdisciplinary approach. Dr. Bulut has contributed to advancing pharmacological research with her findings on natural compounds and coenzyme Q10’s efficacy in mitigating organ dysfunction. Her academic influence extends through her roles as a physician and educator, mentoring emerging researchers in pharmacology. Dr. Bulut’s dedication to drug safety and therapeutic research has not only bolstered her professional reputation but also holds promise for improving patient care and drug efficacy in clinical settings.

Professional Profile

Education

Dr. Seval Bulut’s educational background exemplifies her dedication to the fields of medicine and pharmacology. She earned her MD from Atatürk University Faculty of Medicine in 2001, embarking on her journey as a physician committed to improving patient outcomes. Dr. Bulut later transitioned to academia, pursuing a doctoral program at Erzincan Binali Yıldırım University’s Institute of Health Sciences, Department of Medical Pharmacology. In 2024, she completed her PhD with a thesis titled “The Effect of Liv-52 on Favipiravir-Induced Hepatotoxicity in Rats: Biochemical and Histopathological Evaluation,” demonstrating her keen focus on pharmacology, particularly in drug-induced toxicity. This advanced education has equipped Dr. Bulut with a strong foundation in both clinical and research aspects of pharmacology, enabling her to investigate the biochemical mechanisms of drug interactions and develop therapeutic strategies for organ protection. Her academic journey reflects a consistent focus on integrating medical practice with pharmacological research to address real-world health challenges.

Professional Experience

Dr. Bulut’s professional experience is rooted in her dual roles as a clinician and researcher. She initially practiced medicine across various health institutions from 2001 to 2010, gaining valuable hands-on experience that provided her with a comprehensive understanding of patient care. Transitioning to a Family Physician role between 2010 and 2024, she developed a strong patient-focused perspective, which later became integral to her research approach. Currently, Dr. Bulut serves as an Assistant Professor in the Department of Pharmacology at Erzincan Binali Yıldırım University. In this academic role, she has combined her clinical insights with research expertise, conducting studies on pharmacological interventions to protect against drug-induced organ damage. Her extensive background in clinical medicine complements her current research endeavors, where she investigates the biochemical and histopathological mechanisms of pharmacological agents. This blend of professional experience positions Dr. Bulut as a knowledgeable researcher who brings both theoretical and practical insights to her field.

Research Interests

Dr. Seval Bulut’s research interests lie at the intersection of pharmacology, toxicology, and therapeutic interventions. She is particularly focused on understanding drug-induced toxicity and the protective effects of natural compounds on organ systems. Her work has centered on evaluating the biochemical and histopathological mechanisms of various pharmacological agents, including the impact of drugs such as favipiravir on liver health. Dr. Bulut’s studies also explore natural compounds like coenzyme Q10 and cinnamon extract for their potential to mitigate organ dysfunction, particularly in kidney and liver applications. Additionally, she has examined the effects of pharmaceutical compounds on reproductive health, as well as protective pharmacological strategies for conditions such as ischemic ocular syndrome. Her research contributes to improving drug safety and efficacy, providing insights that could lead to safer clinical applications and therapeutic innovations. Through her interdisciplinary research, Dr. Bulut aims to enhance the understanding of pharmacodynamics and pharmacokinetics in therapeutic contexts.

Research Skills

Dr. Seval Bulut has developed a broad set of research skills essential to her pharmacological studies. She is adept in designing and conducting in vivo experiments, specifically using animal models to assess drug efficacy and toxicity. Her skills in biochemical and histopathological analysis are evidenced in her research on drug-induced organ toxicity, where she utilizes various biochemical markers and staining techniques to evaluate cellular and tissue changes. Dr. Bulut is also proficient in data analysis and interpretation, crucial for her work in pharmacology and toxicology, where she frequently analyzes complex datasets to draw meaningful conclusions about drug interactions and therapeutic effects. Additionally, she is skilled in the ethical and methodological aspects of animal research, ensuring that her studies meet rigorous scientific standards. Her collaborative skills are reflected in her ability to work alongside other professionals, contributing to a multidisciplinary approach in her studies on pharmacological agents and natural compounds.

Awards and Honors

Dr. Seval Bulut’s academic and professional achievements have earned her recognition in the scientific community. Her prolific publication record includes 45 research articles indexed in SSCI and SCIE, which demonstrates her commitment to advancing pharmacological research. These publications span influential journals, highlighting her research’s impact and relevance in the field. Dr. Bulut’s focus on drug safety, natural therapeutics, and organ protection has led to invitations to present her findings at international congresses, further establishing her as a respected voice in pharmacology. Additionally, her progression from a practicing physician to a PhD-holder and Assistant Professor in a highly specialized research area reflects her dedication to both medical practice and academia. Although specific awards are not listed, her consistent scholarly contributions and active research agenda signal her as a promising candidate for future awards recognizing excellence in research and contributions to pharmacology. Her work holds significant implications for clinical safety and therapeutic advancements, which are critical areas of modern medical research.

Conclusion

Dr. Seval Bulut is a strong candidate for the Best Researcher Award due to her significant contributions to pharmacological research and her commitment to addressing drug safety and therapeutic efficacy. Her expertise, publication volume, and applied research focus on organ protection and biochemical evaluation highlight her as an impactful researcher. Continued emphasis on international collaboration, active conference participation, and funding pursuit could further elevate her profile and ensure sustained research advancements.

Publications Top Notes

  1. Title: Effect of ethyl acetate extract from Usnea longissima on chemotherapy-associated multiple organ dysfunction in rats
    Authors: Bingul, E., Bulut, S., Mammadov, R., Suleyman, H., Mendil, A.S.
    Journal: Biomedicine and Pharmacotherapy
    Year: 2024
    Volume: 181
    Article ID: 117636
  2. Title: The hormonal mechanism of the effects of meperidine, sertraline, tianeptine, and their combinations on reproductive functions in female rats
    Authors: Yilmaz, B.K., Suleyman, Z., Suleyman, B., Coban, T.A., Suleyman, H.
    Journal: Biomedicine and Pharmacotherapy
    Year: 2024
    Volume: 178
    Article ID: 117160
  3. Title: Lacidipine, thiamine pyrophosphate and their combination on the ocular ischemic syndrome induced by bilateral common carotid artery ligation
    Authors: Cicek, I., Somuncu, A.M., Altuner, D., Tastan, T.B., Suleyman, H.
    Journal: International Journal of Ophthalmology
    Year: 2024
    Volume: 17, Issue 5
    Pages: 815–821
  4. Title: Effects of adenosine triphosphate, Lacidipine, and Benidipine on 5-fluorouracil-induced kidney damage in rats
    Authors: Dagel, T., Altuner, D., Suleyman, B., Gulaboglu, M., Suleyman, H.
    Journal: European Review for Medical and Pharmacological Sciences
    Year: 2024
    Volume: 28, Issue 6
    Pages: 2538–2549
  5. Title: Comparative study of the protective effects of coenzyme Q10 and cinnamon extract on possible kidney damage and dysfunction of amiodarone in rats
    Authors: Ekici, O., Gul, A., Keskin, E., Gunay, M., Suleyman, H.
    Journal: Clinical and Experimental Nephrology
    Year: 2024
  6. Title: Protective effects of thiamine pyrophosphate and cinnamon against oxidative liver damage induced by an isoniazid and rifampicin combination in rats
    Authors: Yeter, B., Mammadov, R., Koc, Z., Gulaboglu, M., Suleyman, H.
    Journal: Investigacion Clinica (Venezuela)
    Year: 2024
    Volume: 65, Issue 3
    Pages: 321–334
  7. Title: Protective effect of cinnamon extract against cobalt-induced multiple organ damage in rats
    Authors: Isik, B., Suleyman, B., Mammadov, R., Coban, T.A., Suleyman, H.
    Journal: Frontiers in Pharmacology
    Year: 2024
    Volume: 15
    Article ID: 1384181
  8. Title: Role of L-, N- and T-type calcium channels in achieving maximum analgesic and minimum toxic effect of tramadol
    Authors: Yilmaz, M., Suleyman, B., Mammadov, R., Coskun, R., Suleyman, H.
    Journal: Acta Poloniae Pharmaceutica – Drug Research
    Year: 2024
    Volume: 81, Issue 1
    Pages: 135–143
  9. Title: Protective Effect of Ramipril Against Oxidant and Proinflammatory Cytokine Damage Induced by Ischemia-Reperfusion in Ovarian Tissue in Rats
    Authors: Ulug, P., Nayki, U., Mammadov, R., Coban, T.A., Suleyman, H.
    Journal: Transplantation Proceedings
    Year: 2024
    Volume: 56, Issue 1
    Pages: 215–222
  10. Title: Effect of pycnogenol on ischemia/reperfusion-induced oxidative and inflammatory damage in the ovaries of rats
    Authors: Dinc, K., Kiremitli, S., Suleyman, B., Altuner, D., Suleyman, H.
    Journal: Tropical Journal of Pharmaceutical Research
    Year: 2023
    Volume: 22, Issue 11
    Pages: 2297–2303